Torch study erlotinib treatment

TORCH: A Study of Tarceva or Chemotherapy for the ...

★ ★ ★ ★ ★

TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer (TORCH) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.

TORCH: A Study of Tarceva or Chemotherapy for the ...

Front-line erlotinib in unselected patient with advanced ...

★ ★ ★ ★ ☆

The lack of OS difference for patients treated with front-line gefitinib or erlotinib versus chemotherapy may be due to the extensive crossing over of subsequent second-line treatment as well as uncontrolled second-line treatment options. In TORCH study, the second …

Front-line erlotinib in unselected patient with advanced ...

TORCH: A Study of Tarceva or Chemotherapy for the ...

★ ★ ★ ☆ ☆

The purpose of this study is to compare first-line erlotinib followed at progression by second-line chemotherapy vs. first-line chemotherapy followed at progression by second-line erlotinib in the treatment of Advanced Non Small Cell Lung Cancer (NSCLC).

TORCH: A Study of Tarceva or Chemotherapy for the ...

Quality of Life Analysis of TORCH, a Randomized Trial ...

★ ★ ☆ ☆ ☆

study was prematurely stopped at the first interim analysis when inferiority of the experimental arm was demonstrated.8 In this article, we report results of QoL analyses during first-line treatment (cisplatin/gemcitabine versus erlotinib) in the TORCH trial, and an exploratory analysis of QoL differ-

Quality of Life Analysis of TORCH, a Randomized Trial ...

The TORCH trial - Carter - Translational Lung Cancer Research

★ ★ ☆ ☆ ☆

The TORCH trial was a randomised, non-inferiority, phase III trial comparing erlotinib given as first-line therapy followed by standard chemotherapy with cisplatin-gemcitabine versus the opposite standard sequence, in unselected advanced NSCLC patients .

The TORCH trial - Carter - Translational Lung Cancer Research

Erlotinib (Tarceva) for the Treatment of Non–Small-Cell ...

★ ★ ★ ★ ☆

Erlotinib (Tarceva) is a small-molecule, orally dosed, anti-cancer drug that inhibits the epidermal growth factor receptor. Randomized, controlled clinical studies have demonstrated that erlotinib significantly improved survival in patients with previously treated non–small-cell lung cancer and, in combination with chemotherapy, in patients with untreated pancreatic cancer.

Erlotinib (Tarceva) for the Treatment of Non–Small-Cell ...

TORCH Study: How Much Longer Should We Continue to Use ...

★ ★ ★ ☆ ☆

Request PDF on ResearchGate | TORCH Study: How Much Longer Should We Continue to Use Erlotinib in Unselected Patients With Non-Small-Cell Lung Cancer? | TO THEEDITOR: Gridelli et al 1 recently ...

TORCH Study: How Much Longer Should We Continue to Use ...

A phase II study of erlotinib in combination with ...

★ ★ ☆ ☆ ☆

The TORCH study showed median OS of 8.7 months for first-line erlotinib versus 11.6 months for chemotherapy in EGFR unselected patients . ... The SAKK 19/05 study suggested that bevacizumab and erlotinib first-line treatment was feasible with acceptable toxicity and activity (PFS 4.1 …

A phase II study of erlotinib in combination with ...

Quality of Life Analysis of TORCH, a Randomized Trial ...

★ ★ ★ ☆ ☆

Introduction: The TORCH (Tarceva or Chemotherapy) trial randomized patients with advanced non–small-cell lung cancer to first-line erlotinib followed by second-line cisplatin/gemcitabine versus. standard inverse sequence.The trial, designed to test noninferiority in overall survival, was stopped at interim analysis because of inferior survival in the experimental arm.

Quality of Life Analysis of TORCH, a Randomized Trial ...

Erlotinib in Non-Small Cell Lung Cancer Treatment: Current ...

★ ★ ★ ★ ☆

7/1/2007 · Moreover, this trial will allow the evaluation of the relationship between molecular predictors, such as EGFR and K-ras mutational status, and erlotinib treatment response. The aim of the TORCH study is to evaluate, in a randomized fashion, what is the most appropriate and cost-effective sequential approach for erlotinib and chemotherapy in an ...

Erlotinib in Non-Small Cell Lung Cancer Treatment: Current ...

A Trial-Based Cost-Effectiveness Analysis of Erlotinib ...

★ ★ ★ ★ ☆

3/8/2013 · This study emphasizes the importance of the presence of an EGFR gene mutation in assessing the incremental effect and costs of erlotinib as a first-line treatment. Our study may provide a valuable reference for making informed decisions about resource allocation.

A Trial-Based Cost-Effectiveness Analysis of Erlotinib ...

The TORCH trial | Request PDF - ResearchGate

★ ★ ★ ★ ☆

The mainstay of treatment, until recently, has been platinum... We use cookies to make interactions with our website easy and meaningful, to better understand the use of our services, and to ...

The TORCH trial | Request PDF - ResearchGate

TORCH: A Study of Tarceva or Chemotherapy for the ...

★ ★ ★ ☆ ☆

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number): Di Maio M, Gallo C, Leighl NB, Piccirillo MC, Daniele G, Nuzzo F, Gridelli C, Gebbia V, Ciardiello F, De Placido S, Ceribelli A, Favaretto AG, de Matteis A, Feld R, Butts C, Bryce J, Signoriello S ...

TORCH: A Study of Tarceva or Chemotherapy for the ...

Turn on the TORCH before treat your patients: a lesson ...

★ ★ ☆ ☆ ☆

Turn on the TORCH before treat your patients: a lesson from a first line study in advanced NSCLC The first line treatment of (EGFR unselected) stage IV non small cell lung cancer (NSCLC), in Western countries, is driven by the disease (histology) and by the patient [age and performance status (PS)].

Turn on the TORCH before treat your patients: a lesson ...

EGFR Mutation Guides Erlotinib in Advanced Lung Cancer

★ ★ ★ ☆ ☆

"Our results show a significant interaction in progression-free survival, favoring treatment with erlotinib first in EGFR-mutated patients and favoring first treatment with chemotherapy in EGFR ...

EGFR Mutation Guides Erlotinib in Advanced Lung Cancer

First-Line Erlotinib Inferior to Chemo in Advanced Lung Cancer

★ ★ ★ ★ ☆

In another trial of elderly patients, the median overall survival was 11 months. Thus, researchers led by Cesare Gridelli, MD, of San Giuseppe Moscati Hospital in Avellino, Italy, initiated the phase III TORCH (Tarceva or Chemotherapy) trial, testing erlotinib as a first-line treatment for advanced NSCLC.

First-Line Erlotinib Inferior to Chemo in Advanced Lung Cancer

NSCLC patients with EGFR mutations benefit from erlotinib ...

★ ★ ☆ ☆ ☆

4/19/2012 · The TORCH trial was a randomized phase III trial conducted in Italy and Canada, which compared the efficacy of treatment with erlotinib, followed at progression of disease by cisplatin and ...

NSCLC patients with EGFR mutations benefit from erlotinib ...

Quality of Life Analysis of TORCH, a Randomized Trial ...

★ ★ ☆ ☆ ☆

The TORCH (Tarceva or Chemotherapy) trial randomized patients with advanced non–small-cell lung cancer to first-line erlotinib followed by second-line cisplatin/gemcitabine versus. standard inverse sequence. The trial, designed to test noninferiority in overall survival, was stopped at interim analysis because of inferior survival in the experimental arm.

Quality of Life Analysis of TORCH, a Randomized Trial ...

Clinical Research Paper Biomarker analysis of the phase 3 ...

★ ★ ★ ☆ ☆

The TORCH (Tarceva OR CHemotherapy) trial was an Italian-Canadian multicenter, open-label, randomized phase III trial comparing first line erlotinib followed by chemotherapy (cisplatin-gemcitabine) at progression, with the reverse standard sequence of first-line chemotherapy followed by erlotinib, in unselected advanced stage IIIB

Clinical Research Paper Biomarker analysis of the phase 3 ...

First-Line Erlotinib Followed by Second-Line Cisplatin ...

★ ★ ★ ☆ ☆

most clinical and biologic factors.8,9 Therefore, clinical or biologic In first-line treatment, erlotinib added to chemotherapy did factors were not applied in the selection of the study population. not prolong survival.10,11 However, two phase II studies suggested that first-line therapy with erlotinib might be an alternative to chemotherapy ...

First-Line Erlotinib Followed by Second-Line Cisplatin ...

Experience with erlotinib in the treatment of non-small ...

★ ★ ★ ★ ★

In the TORCH study, 760 patients with NSCLC were randomly assigned to a standard platinum regimen followed by erlotinib at the time of progression versus the experimental arm of erlotinib first line followed by chemotherapy at progression. The study was discontinued when an interim analysis revealed that first-line erlotinib was inferior to ...

Experience with erlotinib in the treatment of non-small ...

Erlotinib and bevacizumab versus cisplatin, gemcitabine ...

★ ★ ★ ★ ★

3/18/2015 · Abstract. Erlotinib with bevacizumab showed promising activity in recurrent nonsquamous (NS) nonsmall cell lung cancer (NSCLC). The INNOVATIONS study was designed to assess in first-line treatment of unselected cisplatin-eligible patients this combination compared to cisplatin, gemcitabine and …

Erlotinib and bevacizumab versus cisplatin, gemcitabine ...

Quality of Life Analysis of TORCH, a Randomized Trial ...

★ ★ ☆ ☆ ☆

Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer

Quality of Life Analysis of TORCH, a Randomized Trial ...

1249PCMET EXPRESSION AND ACTIVITY OF FIRST-LINE ERLOTINIB ...

★ ★ ☆ ☆ ☆

Aim: In the TORCH trial, molecularly unselected pts with advanced NSCLC were randomized to erlotinib (E) or cisplatin + gemcitabine (CG) as first lin We use cookies to …

1249PCMET EXPRESSION AND ACTIVITY OF FIRST-LINE ERLOTINIB ...

BioMed Research International - Hindawi Publishing Corporation

★ ★ ★ ★ ★

In clinical practice, the crossover treatment is usually noted when disease progresses. In TORCH trial, the standard treatment (1st chemotherapy/2nd TKIs) is better than experimental treatment (1st TKIs/2nd chemotherapy) in unselected NSCLC patients. However, there is small portion of mutant EGFR patients in TORCH study.

BioMed Research International - Hindawi Publishing Corporation

New analysis helps guide use of erlotinib in advanced non ...

★ ★ ★ ★ ☆

4/18/2012 · Patients with advanced non-small cell lung cancer should only receive treatment with the drug erlotinib before receiving standard chemotherapy if their tumor is known to harbor EGFR mutations ...

New analysis helps guide use of erlotinib in advanced non ...

First-Line Erlotinib Followed by Second-Line Cisplatin ...

★ ★ ★ ★ ☆

In first-line treatment, erlotinib added to chemotherapy did not prolong survival.10,11 However, two phase II studies suggested that first-line therapy with erlotinib might be an alternative to chemotherapy in patients with advanced NSCLC. In the first study,12 single-agent erlotinib produced a …

First-Line Erlotinib Followed by Second-Line Cisplatin ...

New analysis helps guide use of erlotinib in advanced non ...

★ ★ ★ ★ ★

treatment with erlotinib first should only be applied to patients whose tumor is known to harbor EGFR mutation," said Dr Tsao. "Patients with unknown or ... "In summary, the TORCH-BIO study adds

New analysis helps guide use of erlotinib in advanced non ...

EGFR inhibition in non-small cell lung cancer: current ...

★ ★ ★ ★ ☆

1/16/2013 · EGFR inhibition has emerged to be an important strategy in the treatment of non-small cell lung cancer (NSCLC). Small molecule tyrosine kinase inhibitors (TKIs) and mono-clonal antibodies (mAbs) to the EGFR have been tested in multiple large randomized phase III studies alone or combined with chemotherapy, as well as small phase I-II studies which investigated their efficacy as ...

EGFR inhibition in non-small cell lung cancer: current ...

Use of Erlotinib in Advanced Non-Small Cell Lung Cancer ...

★ ★ ★ ★ ☆

Researchers have revealed that patients with advanced lung cancer should only receive treatment with the drug erlotinib if their tumor is known to harbor EGFR mutations.

Use of Erlotinib in Advanced Non-Small Cell Lung Cancer ...

Erlotinib: An EGF Receptor Tyrosine Kinase Inhibitor in ...

★ ★ ☆ ☆ ☆

Erlotinib: An EGF Receptor Tyrosine Kinase Inhibitor in Non-small-cell Lung Cancer Treatment ... followed at progression by erlotinib. The aim of the TORCH study is to evaluate, in a randomized ...

Erlotinib: An EGF Receptor Tyrosine Kinase Inhibitor in ...

The 4717C > G polymorphism in periplakin modulates ...

★ ★ ☆ ☆ ☆

2/20/2019 · The use of EGFR inhibitors on oral squamous cell carcinoma (OSCC) as monotherapy yielded modest clinical outcomes and therefore would benefit from …

The 4717C > G polymorphism in periplakin modulates ...

Experience with erlotinib in the treatment of non-small ...

★ ★ ★ ★ ★

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths. In the last decade, the epidermal growth factor receptor (EGFR) signalling pathway has emerged as one of the most important molecular aberrations, representing an attractive therapeutic target in NSCLC. Drugs interfering with the tyrosine kinase domain of the EGFR (EGFR TKIs), such as erlotinib and gefitinib ...

Experience with erlotinib in the treatment of non-small ...

Who should receive EGFR tyrosine-kinase inhibitors? - The ...

★ ★ ★ ★ ☆

On the basis of initial trials, erlotinib is often used as a treatment for patients with advanced NSCLC who have received previous therapy, but patients without EGFR mutations seem to do better with conventional chemotherapy. The TORCH study

Who should receive EGFR tyrosine-kinase inhibitors? - The ...

TAP Vol 3 Issue 8 by Harborside Press LLC - Issuu

★ ★ ★ ★ ★

Issuu is a digital publishing platform that makes it simple to publish magazines, catalogs, newspapers, books, and more online. Easily share your publications and get them in front of Issuu’s ...

TAP Vol 3 Issue 8 by Harborside Press LLC - Issuu

New Analysis Helps Guide Use Of Erlotinib In Advanced Non ...

★ ★ ★ ★ ☆

4/19/2012 · The TORCH trial was a randomized phase III trial conducted in Italy and Canada, which compared the efficacy of treatment with erlotinib, followed at progression of disease by cisplatin and gemcitabine, against the standard reverse sequence. Erlotinib is a drug that specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase.

New Analysis Helps Guide Use Of Erlotinib In Advanced Non ...

Can EGFR-TKIs be used in first line treatment for advanced ...

★ ★ ★ ★ ★

10/10/2012 · The BR.21 study, a trial focused on Caucasian patients, showed positive results for patients who received erlotinib. After TKIs were shown to be more effective than a placebo treatment, several trials were performed to determine whether TKIs were superior to chemotherapy in advanced NSCLC patients[4 – 11]. Most trials showed that the ...

Can EGFR-TKIs be used in first line treatment for advanced ...

ELCC 2012: New analysis helps guide use of erlotinib in ...

★ ★ ★ ★ ☆

The TORCH trial was a randomized phase III trial conducted in Italy and Canada, which compared the efficacy of treatment with erlotinib, followed at progression of disease by cisplatin and gemcitabine, against the standard reverse sequence. Erlotinib is a drug that specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase.

ELCC 2012: New analysis helps guide use of erlotinib in ...

New analysis helps guide use of erlotinib in ... - EurekAlert!

★ ★ ★ ☆ ☆

Patients with advanced non-small cell lung cancer should only receive treatment with the drug erlotinib before receiving standard chemotherapy if their tumor is known to harbor EGFR mutations ...

New analysis helps guide use of erlotinib in ... - EurekAlert!

Treatment of advanced non small cell lung cancer - Anna ...

★ ★ ☆ ☆ ☆

In patients with advanced NSCLC, the PFS and OS in this study were 3.25 months and 7.9 months, respectively, and the disease control rate was 69% .Results from the TRUST study suggest that erlotinib can benefit a wide range of patients, including those who have previously been thought unlikely to benefit from this treatment .

Treatment of advanced non small cell lung cancer - Anna ...
Body-systems-review-study-sheet.html,Boer-wars-significance-of-study.html,Bond-university-study-rooms.html,Bonded-labour-act-pdf-study.html,Bonent-cht-study-guide.html